PPT-Training package on active tuberculosis drug safety monitoring and management (

aDSM 2023 11 Structure and training objectives for this course amp key references Structure of this training packages 1 Structure of this training packages 2 Background Overview Objectives. Vojtech. EKSLER & Cecilia LIND. Safety. . Unit. Part I:. Introducing SMS for Europe. Introduction (1). “You cannot manage what you cannot measure.”. Kelvin, Kaplan. …so you cannot improve what you cannot monitor.. TUBERCULOSIS. TUBERCULOSIS is an infectious disease caused by Mycobacteria; Mycobacterium tuberculosis & Mycobacterium . bovis. .. MODE OF TRANSMISSION. Inhalation. of droplets. Ingestion . --self swallowing of infected sputum/ or ingestion of . Why do we test?. 1. We want to prevent an outbreak of Tuberculosis in our campus community. 2. We want to find those that are affected and get them treated so you are able to continue to participate in your schooling. . the US Military. LTC . Jamie Mancuso, . July 2012. Paul . B. Keiser, Feb 2014. Walter . Reed Army Institute of Research. Edward Munch. . The Sick Child. . (1885). 2. Outline. Global Burden of Tuberculosis. FTA Annual Drug and Alcohol Program National Conference. March 2016. FTA Substance Abuse Management . . Game plan for this session:. Outline the FTA training requirements (655.14). Reveal training techniques used by superstar trainers. CO, NMRC. 2. Outline. Importance of TB. Clinical . Overview of TB. Active . vs. Latent TB. Active TB diagnosis and treatment. LTBI diagnosis and treatment. 3. Global Burden of Tuberculosis. 9.2 million cases and 1.7 million deaths yearly. CO, NMRC. 2. Outline. Importance of TB. Clinical . Overview of TB. Active . vs. Latent TB. Active TB diagnosis and treatment. LTBI diagnosis and treatment. 3. Global Burden of Tuberculosis. 9.2 million cases and 1.7 million deaths yearly. Eric Bihler. Objectives . Brief overview of epidemiology and transmission. Differentiate between latent and active tuberculosis. Treatment of tuberculosis. Common side effects of therapy. I. ntroduction. Medical Microbiology. : Semester VI. Tuberculosis (TB) is a potentially serious . infection . that mainly affects your . lungs. caused by . Mycobacterium tuberculosis.  (MTB) . bacteria and . The . Dr.. . Mohed. Shaker. A Brief History of Tuberculosis (TB). Tuberculosis (phthisis) described since the time of . Hippocrates (460 BC - 370 BC). . 1689: Doctor Richard Morton . used the term . “consumption”. Courses in Therapeutics and Disease State Management. Learning Objectives (Slide 1 of 2). Identify the risk factors for TB infection and active disease.. Design an appropriate therapeutic plan for latent tuberculosis in immunocompetent, immunocompromised, and special patient populations.. The treatment of drug-susceptible. and drug-resistant tuberculosis. Antwerp, 11 April 2019. Hans L Rieder. Efficacy, effectiveness, efficiency…. Efficacy. What can the drug do? (ideal conditions, simulated in clinical trial settings: factually evaluating . Shah N, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, et al. Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa. Emerg Infect Dis. 2011;17(3):510-513. https://doi.org/10.3201/eid1703.101363. Dr. . Ruchi. . Dua. (Associate Prof). Dept. of Pulmonary Medicine. Learning Objectives. When to suspect Pulmonary Tuberculosis?. How to diagnose?. How to manage a case of drug susceptible Tuberculosis?.